Optimizing Hematology Prior Authorizations with Waystar Clearinghouse

Klivira streamlines prior authorizations for complex hematology treatments, integrating seamlessly with your Waystar Clearinghouse workflows to accelerate revenue cycles and reduce administrative burden.

For hematology practices, managing prior authorizations for high-cost specialty drugs and advanced therapies is a significant operational challenge. Integrating a purpose-built PA automation platform with your existing Waystar Clearinghouse infrastructure is critical for efficiency, compliance, and financial health. This approach minimizes manual intervention and accelerates claims processing.

The Hematology Prior Authorization Landscape

Hematology involves high-cost specialty drugs for conditions like hemophilia, sickle cell disease, and hematologic oncology, including CAR-T cell therapies such as Yescarta and Kymriah. These treatments frequently trigger complex prior authorization requirements, demanding precise clinical documentation and adherence to evolving payer policies. Manual PA processes in this specialty lead to significant delays and potential revenue leakage.

Waystar Clearinghouse in the Hematology Revenue Cycle

Waystar serves as a critical component of the revenue cycle for many hematology practices, handling claims submission, status tracking, and remittance management. While Waystar optimizes the financial transaction flow, the prior authorization process often remains a preceding bottleneck. Integrating PA automation ensures that claims reaching Waystar are pre-authorized, preventing downstream denials and accelerating reimbursement cycles.

Common Prior Authorization Triggers in Hematology

High-cost factor concentrates for hemophilia (e.g., factor VIII: Advate, Adynovate, Hemlibra; factor IX: BeneFIX, Alprolix) requiring ASH guideline adherence.
Specialty drugs for sickle cell disease (e.g., voxelotor/Oxbryta, crizanlizumab/Adakveo, gene therapies like Casgevy, Lyfgenia for SCD).
CAR-T cell therapies (e.g., Yescarta, Kymriah, Breyanzi) with stringent NCCN-based eligibility criteria and prior-line therapy documentation.
Advanced imaging for multiple myeloma (MM/MGUS workup) and other hematologic malignancies.
Bone marrow and stem cell transplant procedures, both autologous and allogeneic.

Integrating Klivira with Waystar Clearinghouse for Hematology PA

Klivira automates the prior authorization workflow, generating requests based on EMR data and submitting them via appropriate payer channels (ePA, X12 278, payer portals). For hematology practices utilizing Waystar Clearinghouse, Klivira ensures that authorization numbers are captured and available for seamless inclusion in claims submitted through Waystar, reducing the risk of technical denials and improving clean claim rates.

Enhancing Efficiency and Compliance in Heme PA

Klivira's platform incorporates ASH and NCCN-aware policy logic, specifically designed for hematologic oncology, hemophilia factor utilization tracking, and CAR-T eligibility documentation automation. This targeted intelligence helps reduce common denial reasons, such as NCCN-compendium gaps or hemophilia factor prophylaxis-vs-on-demand criteria, ensuring claims are robust before reaching Waystar for submission.

EMR and Payer Touchpoints for Hematology Workflows

Our solution integrates with leading EMRs via SMART on FHIR, extracting necessary patient demographics, diagnoses, and ordered treatments. For hematology, this includes specific order types for factor concentrates or specialty drugs. We connect to a broad network of payer portals and support electronic PA standards like X12 278 and NCPDP SCRIPT for PBMs, ensuring comprehensive coverage for hematology payers.

Frequently asked questions

How does Klivira handle specific hematology documentation requirements?

Klivira's policy engine is configured with ASH and NCCN guidelines, automating the collection of necessary documentation such as factor levels for hemophilia, prior-line therapy for CAR-T, and diagnosis confirmation for hematologic oncology, directly from your EMR.

Can Klivira integrate with my existing EMR to support hematology PA workflows?

Yes, Klivira integrates with major EMR systems using industry standards like SMART on FHIR. This allows for seamless data exchange, ensuring that patient information, diagnoses, and treatment plans are accurately captured for prior authorization requests in hematology.

What role does Waystar Clearinghouse play in this integrated PA process?

Waystar Clearinghouse handles the submission of claims to payers. Klivira's integration ensures that prior authorization numbers are obtained and appended to claims *before* they are sent to Waystar, preventing denials due to missing authorizations and streamlining the overall revenue cycle for hematology services.

How does Klivira address common denial reasons for hematology treatments?

Klivira's intelligent automation identifies and flags potential issues based on payer policies and clinical guidelines, such as NCCN-compendium gaps for novel agents or hemophilia factor prophylaxis-vs-on-demand criteria, helping to proactively resolve them before submission.

Does Klivira support prior authorizations for CAR-T cell therapies?

Yes, Klivira provides specialized workflows for CAR-T cell therapies, including support for documentation requirements such as diagnosis confirmation and prior-line therapy per NCCN guidelines, which are critical for securing authorization for these complex treatments.